Introduction
The World Health Organization classification for thyroid tumours still distinguishes two types of non-medullary differentiated thyroid cancer: the papillary thyroid carcinoma (PTC), diagnosed on the basis of characteristic nuclear features, and the follicular thyroid carcinoma (FTC), defined by its capsular and/or vascular invasiveness. However, for decades, conventional histology failed to classify some encapsulated follicular thyroid tumours as benign or malignant because these lesions share overlapping histological features. This already known difficulty is underscored by recent substantial interobserver variability (Hirokawa et al., 2002; Franc et al., 2003; Lloyd et al., 2004) , either in the pathological assessment of thyroid nodules or in the identification of underlying diagnosis criteria, such as papillary nuclear features, vascular and/or capsular invasion. These difficulties are especially relevant in encapsulated differentiated thyroid carcinomas for their belonging to the encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) or the minimally invasive FTC group, and for their ability to harbour predominant oncocytic features. To point out to the clinicians such difficulties, several terminologies have been proposed over time (Williams, 2000) . The term of atypical thyroid follicular adenoma is now restricted to adenomas with pronounced cellular proliferation, less regular cytoarchitectural patterns, lacking evidence of capsular and or vascular invasion. For tumours showing questionable capsular and/or vascular invasion, it is recommended to call them 'follicular tumour of uncertain malignant potential' if papillary carcinoma-type nuclear changes are absent, and 'well-differentiated tumour of uncertain malignant potential' if those nuclear changes are imprecise.
Gene expression profiling by microarray techniques has revealed some tumour subclassifications (Bertucci et al., 2003; Takahashi et al., 2003) . Distinctive gene expression patterns are associated with a wide variety of morphological, biological and clinical parameters. This approach has now begun to be applied to thyroid cancer (Huang et al., 2001; Finley et al., 2004; Giordano et al., 2005; Jarzab et al., 2005; Eszlinger et al., 2006) . Although some studies have included FVPTCs and minimally invasive FTCs, none has examined the challenging group of tumours of uncertain malignancy (T-UM). Only one microarray study has been carried out on minimally or widely invasive follicular carcinomas (Lubitz et al., 2005) . It showed that some minimally invasive carcinomas were subclassified whereas others could be reclassified as either follicular thyroid adenomas (FTAs) or widely invasive carcinomas. These data support the theory of a continuum of tumours from the benign to the malignant. So far, all the microarray studies on thyroid tumours have excluded samples without a clear-cut diagnosis. Since the main objective was to distinguish benign from malignant tumours, the T-UM were ignored. However, given the accuracy of microarray analysis, it may be possible to refine the classification of this group of tumours.
We therefore investigated a group of T-UM using microarrays and taking into account all their underlying counterparts (immune background, cellular atypia, density, mitotic activity, patterns) in comparison with FVPTCs, PTCs, minimally invasive FTCs and FTAs. The results were expected to lead to an improved classification and to better predict true malignancy.
Results

Comparison of gene expression in PTC subtypes
We examined the gene-expression signatures in two variants of PTC, that is, five usual PTCs and eight FVPTCs. These two PTC subtypes were compared using the Student's t-test; the raw P-values were corrected for multiplicity (Benjamini and Hochberg, 1995) over the full set of 5549 expressed genes analysed by the microarrays. The results showed no significant difference (false discovery rate, FDR>0.05) between the two subtypes (data not shown). We therefore treated the PTC tumours as a single class for the rest of the study.
Overexpressed and co-regulated gene clusters in T-UM The expressed genes were clustered hierarchically to discover the correlated genes involved in T-UM. We found five clusters of overexpressed and correlated genes ( Figure 1 ). Underexpressed genes were also present but no cluster was clearly specific to the T-UM samples. Individual sample specificity with respect to the overexpressed clusters is indicated by the mean log-value signatures (bar charts). Only 21 of the 166 tissue samples had a mean log value greater than 0.6, chosen as an empirical cutoff value. These included 11 (85%) PTCs, 7 (70%) T-UM, 1 (1.5%) FTA and 2 (5.3%) oncocytic thyroid (OT) tumours. Some genes known to be markers of the FTC group showed coordinated upregulation with T-UM or PTC, for example the ASTN2 and the GALNT3 genes. The five clusters of overexpressed genes identified were not specific to the other tumours (low log values). This unsupervised method showed that gene regulation occurred in T-UM and PTCs.
Supervised analysis of the gene-expression signatures
We determined the differential genes in each class of thyroid tumour using permutated F-tests followed by post hoc tests (Po0.05). This method allows the simultaneous detection of differential genes for the various classes of tumour. We were thus able to identify the differential genes shared by T-UM and other thyroid tumours (Figure 2 ). We found 66 upregulated and 92 downregulated differential genes for T-UM. There were 23 (35%) upregulated and 37 (40%) downregulated shared genes with the PTCs and Fisher's exact test indicated that these genes were significantly overrepresented (Po0.05). For the other classes of tumour, the number of upregulated shared genes varied from nine to twelve in FTAs, OTs and wild-type (WT) groups, or from three to five in FTCs, autoimmune thyroiditis (AT)/Grave's disease (GD) tumours. Since the OT, FTA and WT classes contained from 24 to 67 samples whereas the FTC and AT/GD classes contained only 3-10 samples, the discrepancy observed is probably explained by a class-size effect. Nevertheless, the OT-, WT-and AT/GD-upregulated shared genes were considered significantly underrepresented (Po0.05). This finding allowed us to select specific candidate marker genes for each class, or pair of classes of tumour. Supplementary Table 1 lists carcinoma-and adenomaspecific genes in T-UM after filtering of the differential T-UM, FTA and PTC genes from those of the other groups. The supervised determination of the differential genes showed that T-UM and PTCs had significant differences with other classes.
The similarity of the gene expression of T-UM with the other classes of tumour was also estimated using the Pearson's r correlation coefficient calculated from the mean class signatures as defined by the differential genes, that is the class centroids ( Table 1) . The similarity between the T-UM and the PTC class was greater (r ¼ 0.47) than between any of the other classes (Po3.33E-05); the FTC class also showed significant similarity (P ¼ 0.003) but non-relevant r value (r ¼ 0.1). The FTA and WT classes were dissimilar compared to the T-UM class of tumours. The dissimilarity between the T-UM and OT or AT/GD classes was greater than any other within the simulations (P ¼ 1), indicating that these classes were significantly dissimilar from the T-UM class. Finally, the two classes of thyroid tumour, T-UM and PTC, had very similar geneexpression signatures. However, we noticed that one PTC presented a divergent signature strongly correlated with the OT class centroids (data not shown). It was the same as in Figure 1 (PTC 152). Two T-UM samples had also negative similarity (T-UM 1 and 3, same ones as in Figure 1 ) and highly correlated with OT or FTA class centroids (data not shown).
Diagnosis potential of the T-UM gene-expression signature To assess the diagnosis potential of the gene-expression signature, we compared the expression signature of a set of 16 predictive genes for each T-UM sample in addition to their pathological score (Figure 3) . The 16 selected genes were highly predictive of both the PTC and the T-UM groups (Supplementary Table 2 ). The pathological score was based on histological criteria and protein expression analysis (immunohistochemistry) of four malignancy candidate markers (HBME-1, galectin-3, CK19 and TPO) as detailed in Supplementary Table 3 The mutational status of the BRAF, RET/PTC and RAS genes was determined for seven PTC, five T-UM and five FTA samples (Table 2) . We also computed the similarity of each sample signature to the PTC class (Table 2; Supplementary Table 4) . We identified molecular anomalies in five of the seven PTCs; one had a BRAF mutation and four had RET/PTC rearrangements. RET/PTC1 rearrangements were also found in three of the T-UM samples that had the poorest molecular similarity with PTC. In contrast, the two T-UM samples without molecular anomalies had higher correlation coefficients (R PTC ¼ 0.45 and 0.34). No mutations were found in the five FTAs. None of the tumours had overlapping mutations or RAS gene mutations. These findings indicated that some T-UM share high similarities with PTCs and questioned whether they should be classified as PTCs.
The diagnosis potential of the gene-expression signatures was validated on a new set of samples by real-time quantitative RT-PCR. This set comprised six T-UM, five FTAs and five PTCs. We measured the expression of 9 genes out of the 16 predictive genes. The hierarchical clustering of the data separated clearly the samples in two groups (Figure 4 ). The overall robustness for these two clusters over 1000 noised data sets was equal to 0.802. The first group contained all the five FTAs and two T-UMs. The second group contained all the five PTCs and four T-UMs. The new T-UM samples were also evaluated and scored by a pathologist (Supplementary Table 3 ). The mean gene-expression signature of the T-UM samples to the PTC group highly correlated to the pathologist's score (r ¼ 0.57) in this independent experiment ( Figure 5 ). From the global hierarchical clustering of the geneexpression data, we extracted five clusters of correlated and upregulated genes in the T-UM samples. Gene-expression levels are colourcoded in the matrix from green (underexpression) to red (overexpression). Samples (columns) are grouped by class and ordered according to their mean log level of expression (bar charts at the bottom). Only the mean signature is shown for the AT/GD, FTA and OT groups. AT/GD, autoimmune thyroiditis/Graves's disease; FTA, follicular thyroid adenoma; OT. oncocytic tumour, T-UM, tumours of uncertain malignancy.
Immunohistochemical evaluation
Immunostaining results for HBME-1, galectin-3, CK19 and TPO for the 10 T-UM are summarized in Supplementary Table 3 and associated to the histological features for each sample. The results of the T-UM 1 and 3 favoured a diagnosis of benignancy because of the negative HBME-1, Gal-3, CK19 and the TPO expression well preserved. On the contrary, the T-UM 16 and 188 were the only ones positive for HBME-1 staining, in relation to their high mean expression signature on Figure 3 .
We explored the mitochondrial immunostaining for the three samples that were divergent on Figure 1 : the sample 152 (FVPTC), and the two T-UM 1 and 3. Immunostaining data for HBME-1, TPO and mitochondria for these three divergent samples are represented on Figure 6 . Mitochondrial staining was 5 and 15% positive for sample 1 and 3, respectively. With the FVPTC sample 152, all the follicular cells took up a Figure 2 Regulated genes of T-UM shared with other classes. Among the differential genes deduced from the 12 classes of thyroid tissue, the T-UM class had 66 upregulated and 92 downregulated genes. The number of regulated genes shared with other classes is reported for the upregulated genes (grey bars) and the downregulated genes (white bars). Significant overrepresentation ( þ ) and underrepresentation (À) were computed by the Fisher's exact test (Po0.05).
Table 1 Similarity of T-UM with the other tissue classes
Classes
Similarity P-value
Abbreviations: AT/GD, autoimmune thyroiditis/Grave's disease; FTA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma; PTC, papillary thyroid carcinoma; T-UM, tumours of uncertain malignancy; WT, wild-type.
Spearman's ρ=0.71
Mean expression Score
Gene expression (log-value) 0.16 0.14 0.12 0.1 0.08 0.06 0.04 0.02 Pathologist's score Figure 3 Diagnosis potential of predictive genes. The mean loglevel expression (grey bars) of the tumours of uncertain malignancy (T-UM) samples, computed on 16 marker genes, is compared to the pathologist's score (triangles). The marker genes were selected to classify PTC and T-UM samples simultaneously. The Spearman's rank correlation coefficient r between the two series of values is equal to 0.71. Figure 4 Hierarchical clustering of an independent set of tumours of uncertain malignancy (T-UM) samples. The gene-expression levels of 14 independent T-UM samples and 9 marker genes were measured by reverse transcription RT-PCR. The normalized and median-centred gene-expression levels were hierarchically clustered. Gene-expression levels are colour-coded in the matrix from green (underexpression) to red (overexpression). The separation of the tree sample in two clusters is supported by a robustness coefficient of 0.802. medium but homogeneous staining with the mitochondrial antibody.
Discussion
Differentiated thyroid follicular carcinomas are usually diagnosed either on the basis of nuclear features, capsular or vascular invasion. However, there is a group of tumours for which, on the basis of the current diagnostic tools (histological criteria, immunomarkers), it is very difficult to establish whether these tumours will eventually behave as malignant or benign disease. In this group of T-UM, diagnostic tools are urgently needed. The aim of this study was to use microarray data to classify T-UM adenomas into one of these three classes of thyroid tumour: benign, malignant versus PTC and malignant versus FTC. Our study of the molecular profiles of T-UM showed that some were correlated with the profiles of the papillary carcinoma classes of thyroid tumour (Table 1) . This suggests that some T-UM are probably true carcinomas. Microarray analysis of eight of the ten T-UM showed significant similarities with PTCs. In front of the low number of FTC samples, a more exhaustive study is necessary to conclude on sample similarity results for the FTC group. The five classical and the eight follicular variants of PTC in our study were considered to constitute a homogeneous class of papillary tumours. Though we chose one of the less stringent ways of correcting for multiplicity, the FDR-controlling procedure defined by Benjamini and Hochberg (1995) , our result must be balanced by the relatively small number of involved PTC samples. Two studies on PTCs and FVPTCs have investigated a large set of FVPTCs (Mazzanti et al., 2004; Giordano et al., 2005) . The first study failed to discriminate between PTCs and FVPTCs on the basis of molecular profiling, whereas the second was able to distinguish between PTCs and FVPTCs because of the high frequency of the RAS gene mutation in the FVPTC group. Nonetheless, Finn et al. (2007) showed differences but strong gene-expression similarity between classical and follicular variant of PTCs.
Differentially expressed genes determined by our training set included CITED1, CTNNA1, DPP4 and CDH3, which are well corroborated as belonging to the PTC class of tumours (Huang et al., 2001; Jarzab et al., 2005) . The 43% mutation frequency in PTCs was consistent with published reports (Nikiforova et al., 2002; Giordano et al., 2005) . We also found a BRAF mutation in a classical PTC sample, as reported in the literature (Nikiforova et al., 2002) . We were able to define a PTC cancer signature, independent of the RET/ PTC or the BRAF mutational profile of the tumours (Table 2 ). In regard to the PTC similarity coefficient, we showed that two PTC samples with either BRAF (sample 141) or Ret/PTC1 (sample 157) mutation were similar (0.69 and 0.61, respectively), whereas two Ret/ PTC1 PTC samples (124 and 173) had dissimilar index (0.53 and 0.79, respectively).
Three of the ten T-UM were strongly correlated with PTCs, whereas five were poorly correlated (Supplementary Table 4 ). Tumours with RET/PTC mutations were The tumour sampling comprised 6-12 samples per case according to size. (À) absent, (7) suspicious, (+) obvious.
Gene expression (log-value)
Spearman's ρ=0.57
Mean expression Score
Pathologist's score Figure 5 Validation of the diagnosis potential. The mean log-level expression (grey bars) of the six independent tumours of uncertain malignancy (T-UM) samples, computed on nine selected marker genes, is compared to the pathologist's score (triangles). The genes were selected from the list of 16 marker genes. The Spearman's rank correlation coefficient r between the two series of values is equal to 0.57.
found in the strongly correlated as well as the poorly correlated groups (Table 2) . Our results may take into account the recent demonstration of Ret/PTC rearrangements in non-neoplastic follicular cells presenting extensive inflammation as in Hashimoto's thyroiditis (Rhoden et al., 2006) . However, high correlation between mutational and expression profiles reinforces the notion that the three T-UM may be carcinomas. In addition, the definition of a pathological score for each T-UM permitted to detect a good correlation between a high pathological score and a signature significantly similar to PTCs (Figure 3) . Therefore, we postulated that this score may be used to identify benign from malignant tumours among the T-UM class. We propose such a scoring system before assigning a tumour to the 'uncertain malignant potential category'. We showed that the expression profile of nine selected genes was able to clearly separate the T-UM into two groups; benign and malignant (Figure 4) and strongly suggest the belonging of some 'at risk of malignancy' T-UM to the PTC class of carcinoma. We suggest that after a selection by the pathological score some T-UM should be classified by our set of nine expression markers into putative PTCs.
Two T-UM (samples 1 and 3) and one FVPTC (sample 152) showed no correlation with either FTCs or PTCs but with the OT or the FTA classes. The FVPTC 152 presented several foci of mitochondrial rich cells that may have modified the gene-expression signature of the tumour. Indeed, since 39 of the 166 thyroid tumours studied were oncocytic tumours, mitochondrial genes were largely represented in our microarray analysis. We have already shown that the homogeneous mitochondrial signature of oncocytic tumours may mask the signature of the putative transformation of a thyroid adenoma into a carcinoma (Baris et al., , 2005 . For the two T-UM, we verified that the mitochondrial staining was weak while the HBME-1, CK19, galectin-3 and TPO results favoured a diagnosis of benignancy. More, we controlled that none of already known genes specifically overexpressed in the widely or minimally invasive FTC classes (Lacroix et al., 2005; Lubitz et al., 2005) correlated with the expression profile of the two lesions (data not shown). The correlation between low score and expression profile of benign tumours was confirmed on the validating set of T-UM for two T-UM samples (13C and 14C, Supplementary Table 3) .
Interestingly, we were able to identify several genes that were specific to the gene-expression signature of T-UM compared to all other benign or malignant signatures (Supplementary Table 1 ). We identified mitogenic signatures involving the cAMP (TSHR) and the mitogenactivated protein kinase (GRB10 and NR2F2) pathways, as well as lymphangiogenesis event (vascular endothelial growth factor-C), as described in the literature (Durick et al., 1996; Du Villard et al., 2000; More et al., 2003; De la Torre et al., 2006) . This may be associated with the proliferative and invasive signature recently identified in the relatively indolent FVPTC (Finn et al., 2007) resembling to our T-UM. The overexpression of TSHR suggests a less aggressive phenotype (Mirebeau-Prunier et al., 2004; Hoffman et al., 2006) . This result confirms that T-UM behave to a special tumour group.
Conclusion
The analysis of microarray data allowed us to characterize the functional relationships between T-UM and PTCs. The mutational and our defined pathological Figure 6 Immunoperoxidase staining of thyroid tissue sections. Nuclear features and immunohistochemistry of the two atypical adenomas (samples 1 and 3) and the follicular variant of PTC (sample 152) in which the cancer signatures were not correlated with follicular or papillary carcinoma. Original magnification Â 40. Hematoxylin-eosin (a, sample 1; b, sample 3; c, sample 152). Immunoperoxidase staining for the respiratory chain complex IV subunit (d, sample 1; e, sample 3; f, sample 152), HBME-1 (g, sample 1; h, sample 3) and TPO (i, sample 1; j, sample 3).
status of the tissues allowed us to classify some T-UM either as benign or as putative PTCs. Here we show that the molecular signature of the tumour can help to refine the classification of T-UM and, in particular, allow to the identification of tumours at risk for malignancy.
Materials and methods
Tissue samples
The microarray analysis concerns 93 samples of thyroid tumours belonging to four classes-PTC, FTC, FTA and T-UM-in accordance with the WHO 2004. The samples included 13 PTCs (5 classical and 8 follicular variants), 3 FTCs, 67 FTAs and 10 T-UM. Histological features of the 10 T-UM are summarized in Table 3 . The FTA group included macro-and microfollicular adenomas originating from single nodules, and adenomas originating from the largest nodule of multi-nodular goitres. Three groups, comprising a total of 73 thyroid tissue samples served as controls. The WT group contained 24 normal samples; the AT/GD group (10 samples) included samples of autoimmune thyroiditis and GD; and the OT group (39 samples) included oncocytic adenomas and carcinomas. All thyroid tissue samples, obtained from the Ambroise Pare´Hospital (Paris, France) and the Angers University Hospital (France), were rendered anonymous before beginning the study.
Microarrays
RNA extraction, cDNA preparation and hybridization, scanning and image analysis of the arrays were done according to protocols of the manufacturer (http://tagc.univ-mrs.fr/ plateforme/protocoles/) and as previously described , as was probe-set intensity estimation and normalization. Each microarray contained 9216 spotted probes including controls and 8862 cDNA human clones. Genes with an expression similar to the background and genes with missing values over an entire sample class were withdrawn from the analysis. Thus, 5549 genes were expressed and included to the analysis. All data were subjected to print-tip Lowess normalization (Yang et al., 2002) . The microarray data have been deposited in NCBIs Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO series number GSE6339.
Data analysis and statistical methods
Statistical tests were done with R Bioconductor statistical software (Gentleman et al., 2004) . PTC subtypes were compared by Student's t-tests and multiplicity adjustments using FDRcontrolling procedure (Benjamini and Hochberg, 1995) .
Hierarchical clustering of the data was computed on logtransformed, median gene-centred and normalized data using average linkage and uncentred correlation distances. Computations and visualization were done with Cluster and TreeView software (Eisen et al., 1998) , and with BRB ArrayTools v3.6.0b2 developed by Dr Richard Simon and Amy Peng Lam. The biological activity of genes with known functions was determined using the web tool FatiGO with the Gene Ontology database (Al-Shahrour et al., 2004) .
Differential genes were defined for the seven classes of tissue by permutated non-parametric two-sided F-tests (FDR ¼ 5% for 1000 permutations). Multiple-test correction on raw P-values was done by the single-step maxT procedure (Ge et al., 2003) . Up-and downregulated genes were identified by post hoc two-sided t-tests comparing one class to the others (Po0.05, unadjusted).
In the similarity analysis, we defined a centroid of a class as the signature of its mean gene-expression profiles. Similarity was defined as the correlation coefficient of two centroids, or of a sample signature and a centroid. P-values were generated from 30 000 bootstrapped data sets.
The list of 16 predictive genes was generated by using the six prediction methods implemented in BRB ArrayTools (compound covariate predictor, Bayesian compound covariate, diagonal linear discriminant analysis, K nearest neighbours (for K ¼ 1 and 3), nearest centroid and support vector machines) and a cutoff equal to 1E-08 for univariate feature selection. The 0.632 þ cross-validation method was used to compute mis-classification rate.
Detection of mutations and rearrangements DNA and RNA isolation and cDNA synthesis DNA and RNA were isolated using the guanidium isothiocyanate procedure (Trizol Reagent, Invitrogen Life Technologies, Gaithersburg, MD, USA). Quantification, degradation and DNA contamination of RNA were assessed using an RNA 6000 Nano Assay kit (Agilent Technologies, Palo Alto, CA, USA). Reverse transcription was performed on 1 mg of RNA with Advantage RT-for-PCR kit (Clontech Laboratory, Palo Alto, CA, USA) following the manufacturer's recommendations.
DNA and cDNA sequencing The mutational status for BRAF, RET/PTC1, RET/PTC3 and RAS genes was determined for seven PTCs, five T-UM and five macrofollicular FTAs. The PCR reactions were performed on 5 ml cDNA to look for RET/PTC rearrangements, or 5 ml DNA for BRAF and RAS mutations using the HotGoldstar DNA polymerase according to the manufacturer's recommendations (Eurogentec, Seraing, Belgium). The primers used to amplify Ret/PTC1 were 5 0 -AGA-TAG-AGC-TGG-AGA-CCT-AC-3 0 and 5 0 -TG C-AGG-CCC-CAT-ACA-ATT-TG-3 0 , and those used to amplify Ret/PTC3 were 5 0 -AGA-TAG-AGC-TGG-AGA-C CT-AC-3 0 and 5 0 -CAT-GCC-AGA-GCA-GAA-GTC-A-3 0 . The primers flanking exon 15 of the BRAF gene were 5 0 -TC C-TTT-ACT-TAC-ACC-TCA-G-3 0 and CAT-CTC-AGG-GC C-AAA-AAT-3 0 . Exon 2 of the N-Ras gene was amplified using primer sequences described elsewhere (Di Cristofaro et al., 2006) . Amplified fragments were purified and directly sequenced on a CEQ 8000 apparatus, using a CEQ DTCS Quick Start Kit (Beckman Coulter, Fullerton, CA, USA) following the manufacturer's instructions.
Histological samples and immunohistochemistry
All the histological diagnosis corresponding to the studied cases included in the study were reviewed (BF, ST).
T-UM tissues samples The T-UM cases included in the study measured from 1.8 to 5 cm in largest diameter. According to the size of the tumour, 5-12 samples comprising the tumour/ normal tissue interface were analysed (Kononen et al., 1998) . To precisely determine whether the tumours classified T-UM in the study fit with the literature definitions the following criteria: -(1) presence or absence of questionable PTC nuclear features, (2) questionable capsular and/or vascular invasion (3) worrisome cellular and cytoarchitectural features were analysed, and quoted 0 if absent, 1 if suspicious and 2 if obvious. In addition, the expression of four markers known as candidate markers for malignancy was analysed by immunohistochemistry for each of the T-UM cases: HBME-1, galectin-3, cytokeratin 19 and quoted 0 if absent, 1 if expressed in less than 50% of tumour cells, 2 if more than 50% of the cells were positively stained and TPO quoted 0 if expressed in 80% or more of the tumour cells, 1 is expressed between 50 and o80% and 2 when expressed o50% (De Micco et al., 1999) . All the data are presented in the Supplementary Table 2, in addition to an individual score obtained by summing in each case the histological and immunohistochemical quoted variables.
Immunohistochemistry The T-UM immunohistochemical study was performed on a tissue array prepared from the 24 specimens. Representative areas containing the tumour and the control tissue were selected (BF). Double triplicate tissue cores with a diameter of 0.6 mm were taken from each tumour and corresponding tissue specimen (Beecher Instruments, USA), and arrayed on a recipient paraffin block, using standard procedures (Kononen J, Nat Med 1998, 4844-847.) . Consecutive tissue sections (4 mm) were cut from each arrayed paraffin block and prepared on pathological slides. Sections were de-paraffinized in xylene followed by 0.3% hydrogen peroxide in methanol at room temperature for 20 min for blocking endogenous peroxidase. After rehydratation, antigen retrieval, immunostaining was performed with the following primary antibodies: anti-galectin-3 (diluted 1/300, from Novocastra, UK), anti-HBME-1 mesothelial (diluted 1/50, from Dako, Glostrup, Denmark), anti-CK19 (diluted 1/100, Dako), TPO MoAb47 (diluted 1/10, Biocytex, France) incubated overnight at þ 4 1C and a universal streptavidinbiotin-peroxidase kit (LSAB, Dako). For samples PTC152, T-UM 1 and T-UM 3, a 60 kDa anti-mitochondrial (clone 113-1) antibody from Biogenex (dilution 1/300, San Ramon, CA, USA) was used to explore the mitochondrial richness of these divergent tumours. The LSAB kit was used according to the manufacturer's instructions. Peroxidase activity was revealed with a commercial 3,3 0 diaminobenzidine-H2O2 kit (Dako). For negative control slides, the primary antibody was either omitted or replaced by a suitable concentration of normal immunoglobulin G of the same species.
Quantitative RT-PCR analysis Real-time quantitative PCR was performed on cDNA originating from 16 thyroid tumour samples, independent from the samples used for microarray analysis. We quantified the expression of nine selected genes on six T-UM, five FTA and five PTC samples, using SYBR Green I dye as fluorescent signal (iQ sybrGreen supermix, Bio-Rad, Hercules, CA, USA) and according to manufacturer's recommendations for the Chromo4 apparatus (Bio-Rad). The 9 genes explored were: CDH3, CLDN1, ECM1, CITED1, MRC2, ABCC5, DPP4, ABCC3 and CAPN3. The amount of cDNA for the genes selected was normalized by the quantification of the b-actin. Primer list used for quantitative PCR is given in Supplementary Table 3 . Each sample was assayed in duplicate. Negative controls were included in the amplification reactions. The specificity of amplification from each primer pair was attested by plotting the melting curves of products using the Opticon software.
The standard PCR products were generated from plasmids containing the appropriate cDNA insert as template. The sequence-specific standard curve was plotted using serial dilutions of the target gene standard PCR product, and the same primers were used to amplify the cDNA template.
